Experimental combo aims to boost immune attack on tough melanoma

NCT ID NCT05089370

Ongoing Disease control Sponsor: University of Colorado, Denver Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This early-phase trial tests whether adding an oral drug (decitabine/cedazuridine) to the immunotherapy nivolumab can help the immune system better fight mucosal melanoma, a rare and aggressive skin cancer. The study includes 8 adults with advanced disease that cannot be surgically removed. Researchers are primarily checking safety and the right dose, while also looking for signs of tumor shrinkage.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Decitabine/cedazuridine (DEC-C) combined with nivolumab
What this could lead to: If successful, this combination could offer a new treatment option for mucosal melanoma, a rare and hard-to-treat skin cancer.
What could go wrong: This is a very small, early-phase trial with only 8 participants, so results may not apply broadly. The combination may cause side effects or fail to improve outcomes.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for MALIGNANT MELANOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

melanoma mucosal melanoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

MALIGNANT MELANOMA

Contacts and locations

Locations

University of Colorado Hospital

Aurora, Colorado, 80045, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.